Welcome to our dedicated page for Electrocore SEC filings (Ticker: ECOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to electroCore, Inc. (Nasdaq: ECOR) SEC filings, offering a detailed view of how the company reports its activities as a commercial-stage bioelectronic medicine and wellness business. electroCore focuses on non-invasive neuromodulation and bioelectronic technologies, including its gammaCore nVNS and Quell neurostimulator prescription products and its Truvaga and TAC-STIM wellness and performance devices.
Through forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q, investors can review discussions of electroCore’s business, risk factors, financial condition, and operating results. Current reports on Form 8-K, several of which are referenced in the input data, disclose material events including quarterly financial results, private placements of common stock to satisfy specific obligations, and changes in the composition and leadership of the board of directors.
Other filings may cover topics such as stockholder votes on charter amendments, advisory votes on executive compensation, and the appointment of new independent directors or committee members. Together, these documents outline electroCore’s governance practices, capital structure developments, and key financial metrics over time.
On Stock Titan, these SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the contents of lengthy reports, highlight important sections of 10-K and 10-Q filings, and clarify the implications of Form 8-K disclosures. Users can also review insider-related filings such as Form 4, where available, to see reported transactions by directors and officers. This combination of primary documents and AI-generated insights is intended to make electroCore’s regulatory record more accessible to a wide range of readers.
electroCore, Inc. director Thomas J. Errico exercised warrants to acquire a total of 42,055 shares of common stock, with 22,803 shares exercised at an exercise price of $4.35 per share and 19,252 shares at $6.43 per share.
Following these exercises, his directly owned common stock is reported at 350,071 shares. A footnote explains this includes 259,106 shares owned directly, 1,296 shares held by a family trust, 11,000 shares held by a trust for his benefit, 26,615 unvested shares underlying deferred stock units, and 52,054 shares that have vested from prior deferred stock units.
electroCore, Inc. is a bioelectronic technology company focused on non-invasive neuromodulation devices and wellness products. Its main commercial offerings are the prescription gammaCore vagus nerve stimulation system for primary headaches and Quell Fibromyalgia for chronic pain, plus Truvaga and TAC-STIM wellness devices.
The company relies heavily on government and health-system customers: U.S. Department of Veterans Affairs facilities generated 71.2% of 2025 revenue, and U.K. NHS sales under the MedTech Funding Mandate added 4.4%. As of March 13, 2026, 8,083,558 common shares were outstanding and the June 30, 2025 non‑affiliate equity market value was $27,950,688.
electroCore highlights the need for additional capital, concentration of revenue in a few large customers, ecommerce and pricing risks, regulatory and reimbursement uncertainty in the U.S. and U.K., cybersecurity and FTC compliance exposure, a material weakness in internal controls, and Nasdaq listing and debt covenant risks.
electroCore, Inc. reported strong top-line growth for 2025 while remaining loss-making and announced key leadership changes. Net sales for the year ended December 31, 2025 rose to $32.0 million, up about 27% from 2024, driven by 25% growth in U.S. prescription revenue and a 97% increase in general wellness sales. Gross profit increased to $27.8 million with gross margin improving to 87% from 85%.
Operating expenses rose to $40.9 million, reflecting higher sales and marketing and additional legal, IT, and bad debt costs. GAAP net loss widened to $14.0 million, or $1.65 per share, while adjusted EBITDA net loss improved slightly to $8.7 million. Total cash, cash equivalents, and marketable securities were $11.6 million at year-end and stockholders’ equity showed a deficit of $1.7 million. For 2026, the company guides to roughly 30% annual revenue growth. CEO Dan Goldberger will retire effective April 1, 2026, with CFO Joshua Lev becoming interim President and Michael Fox joining as Chief Operating Officer.
electroCore, Inc. Chief Financial Officer Lev Joshua S. reported new equity awards in the company’s common stock. On January 26, 2026, he acquired 2,889 shares at a price of $0 and a separate 25,000-share award, both held directly.
The 25,000-share award represents restricted stock units that vest in three equal 33% installments on each of the first, second, and third anniversaries of the grant date, subject to continued service. Unvested portions can also vest if he is terminated without cause or resigns for good reason within two years after a change in control, under the company’s Executive Severance Policy. His reported beneficial ownership after these transactions is 49,556 shares, including 21,667 shares tied to previously granted restricted stock units with vesting dates in 2027 and 2028.
electroCore CEO Daniel S. Goldberger reported new equity awards in the company. On January 26, 2026, he acquired 20,375 shares of electroCore common stock at $7.47 per share and received a grant of 26,000 restricted stock units at no cost.
The new restricted stock units vest in three equal installments on the first, second, and third anniversaries of the grant date, subject to continued service, and may also vest upon certain qualifying termination events following a change in control. After these transactions, Goldberger beneficially owned 338,940 shares of electroCore common stock, including shares underlying previously granted restricted stock units with future vesting dates.
electroCore, Inc. reported that it has issued a press release providing a business update, including select unaudited preliminary financial guidance for the fourth quarter and full year ended December 31, 2025. This information is being shared with the market through a press release and an accompanying investor presentation.
The company’s executive officers plan to use an investor presentation, filed as an exhibit, in upcoming meetings with investors and analysts. The preliminary figures are based on management estimates and have not been audited or reviewed by the company’s independent registered public accounting firm, so they may change and any changes could be material. The company emphasizes that these disclosures are being furnished, not filed, which limits certain legal liabilities and keeps the information from automatically becoming part of other SEC filings unless specifically incorporated by reference.
electroCore, Inc. Chief Financial Officer reports stock sale and updated holdings. On 12/04/2025, the CFO sold 2,500 shares of electroCore common stock at a weighted average price of $5.05 per share, in a single reported transaction coded as a sale. After this transaction, the reporting person beneficially owns 21,667 shares of common stock.
These 21,667 shares are issuable under previously granted restricted stock units that vest over time. One grant covers 10,000 shares that are scheduled to vest in three annual installments on January 15 of 2026, 2027 and 2028. A second grant covers 11,667 shares, of which 1,000 have already vested and are eligible for sale, and 10,667 are scheduled to vest in two installments on January 12, 2026 and January 12, 2027. The vesting of these awards depends on the CFO’s continued service and includes provisions for accelerated vesting in certain termination events following a change in control, as defined in the company’s Executive Severance Policy.
electroCore (ECOR) filed a Form 4 for its CFO. On 11/12/2025, the executive sold 2,166 shares of Common Stock at a weighted average price of $6.18, with trade prices ranging from $6.0602 to $6.31. Following the sale, the reporting person beneficially owns 23,667 shares.
This balance includes shares issuable under previously granted RSUs: 10,000 scheduled to vest on January 15, 2026 (3,333), January 15, 2027 (3,333), and January 15, 2028 (3,334); and 13,667 of which 3,000 have vested and 10,667 are set to vest on January 12, 2026 (5,333) and January 12, 2027 (5,334), subject to service and change-in-control provisions.
electroCore (ECOR) reported higher Q3 results but remained unprofitable. Net sales were $8.689 million for the quarter, up from $6.554 million a year ago, driven by prescription devices and wellness products. Gross profit was $7.470 million, offset by operating expenses of $10.354 million, resulting in a net loss of $3.405 million, or $0.40 per share. For the nine months, net sales reached $22.789 million versus $18.136 million.
Liquidity improved with cash, cash equivalents, restricted cash and marketable securities totaling $13.201 million as of September 30, 2025. Long‑term debt stood at $6.526 million after a $7.5 million Avenue term loan bearing at least 12.50% interest, with up to $2.5 million convertible at $8.4625 per share and a potential additional $4.5 million Tranche 2. Stockholders’ equity shifted to a deficit of $1.073 million. Sales to the U.S. Department of Veterans Affairs accounted for 69.9% of Q3 net sales. The company also maintains a $20 million ATM program and a $100 million shelf.
electroCore, Inc. furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025 and providing updated guidance for the fourth quarter and full year 2025.
The press release is attached as Exhibit 99.1. The company notes that, except for information relating to Adjusted EBITDA net loss from operations and its reconciliation to GAAP, the information in Items 2.02 and 9.01, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.